首页 | 本学科首页   官方微博 | 高级检索  
     

培美曲塞二线治疗老年晚期非小细胞肺癌的临床观察
引用本文:龚志敏,孙秋实,杜珂. 培美曲塞二线治疗老年晚期非小细胞肺癌的临床观察[J]. 陕西肿瘤医学, 2012, 0(10): 2075-2077
作者姓名:龚志敏  孙秋实  杜珂
作者单位:[1]襄阳市中心医院肿瘤科,湖北襄阳441021 [2]武汉大学医学院研究生院,湖北武汉430073
摘    要:目的:探讨培美曲塞二线治疗老年晚期非小细胞肺癌的疗效及不良反应。方法:老年晚期非小细胞肺癌患者34例,采用培美曲塞500 mg/m2,静脉滴注,第1天;21d为1周期,至少2周期后评价疗效。结果:有效率(RR)为14.7%,中位TTP 3.2个月,中位生存期7.9个月。主要毒副反应为骨髓抑制及消化道反应。结论:培美曲塞二线治疗老年晚期非小细胞肺癌的近期疗效较好,且患者耐受性好,值得临床推广。

关 键 词:非小细胞肺癌  化疗  培美曲塞

Effect of pemetrexed in the second line treatment elderly patients with advanced non-small cell lung cancer
GONG Zhimin,SUN Qiushi,DU Ke. Effect of pemetrexed in the second line treatment elderly patients with advanced non-small cell lung cancer[J]. Shaanxi Oncology Medicine, 2012, 0(10): 2075-2077
Authors:GONG Zhimin  SUN Qiushi  DU Ke
Affiliation:1Departmentment of Oncology,Xiangyang Hospital,Tongji Medical Colledge,Huazhong University of Science and Technology,Hubei Xiangyang 441021,China;2Medical Colledge of Wuhan University,Hubei Wuhan 430073,China.
Abstract:Objective:To evaluate the efficacy and the side-effects of pemetrexed as second-line treatment of elderly patients with advanced non-small cell lung cancer.Methods: Thirty-four elderly patients with advanced non-small cell lung cancer accepted the chemotherapy of pemetrexed 500mg/m2 on day 1.Three weeks as a circle.The effic acy and the side-effects were evaluated at least after two circles.Results: The total effective rate was 14.7%.The median time to progress was 3.2 months and the median survival was 7.9 months.The main side-effects were myelosuppression,nausea and vomiting.Conclusion: Pemetrexed in the second line of treatment of elderly patients with advanced non-small cell lung cancer is effective and with low side-effects.
Keywords:non-small cell lung cancer  chemotherapy  pemetrexed
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号